Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Addex Therapeutics ( (CH:ADXN) ) has issued an update.
Addex Therapeutics has led a CHF 2 million investment in Stalicla, a company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. This strategic investment aims to advance Stalicla’s autism-focused drug candidates and support its corporate activities, reinforcing Addex’s commitment to precision therapeutics in CNS disorders. The collaboration is expected to enhance the development of personalized treatment options for underserved patient populations, with Addex CEO Tim Dyer joining Stalicla’s Board of Directors as Chairman.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing novel small molecule allosteric modulators for neurological disorders. The company is advancing drug candidates for brain injury recovery and substance use disorders, and holds a significant equity interest in Neurosterix LLC, which focuses on allosteric modulator programs for various neurological conditions. Addex is listed on both the SIX Swiss Exchange and NASDAQ Capital Market.
Average Trading Volume: 190,504
Current Market Cap: CHF11.02M
Learn more about ADXN stock on TipRanks’ Stock Analysis page.